York Charles N II
COO and CFO
York Charles N II has filed 3 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Apr 23, 2026.
On the most recent filing, York Charles N II is listed as COO and CFO at Day One Biopharmaceuticals, Inc. Inside the rolling window, York Charles N II reported no open-market purchases and 2 open-market sales totaling $107K in DAWN. The largest disclosed transaction in the window is a sale of 6,065 DAWN shares on Feb 17, 2026, worth $70K.
Companies traded
Other insiders at DAWN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$107K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has York Charles N II made?
York Charles N II has filed 3 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.
Which companies does York Charles N II trade?
York Charles N II has filed SEC Form 4 disclosures for 1 company, including DAWN.
When was York Charles N II's most recent SEC Form 4 filing?
York Charles N II's most recent SEC Form 4 filing on Tracefour is dated Apr 23, 2026.
What is York Charles N II's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, York Charles N II is listed as COO and CFO.
What is York Charles N II's total buy and sell value in the current window?
Inside the rolling retention window, York Charles N II bought $0 and sold $107K based on SEC Form 4 filings.
What was York Charles N II's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,065 DAWN shares on 2026-02-17, worth $70K, per SEC Form 4 filings.